MCL1 and breast carcinoma: Importantly, ER-positive breast cancer cell lines adapt to MCL-1 or BCL-XL inhibition through BIM sequestration by the respective uninhibited pro-survival BCL-2 family protein, and this could be harnessed therapeutically through sequential treatment to liberate BIM and stimulate activation of BAX/BAK [129].